Identification of antigenic peptides from multiple myeloma cells

US8075895B2 · kind B2 · utility

Assignee

• Janssen Pharmaceutica NA · BE

Inventors

• Zeling Cai · San Diego, US
• Wei Shi · 安丰镇, CN
• Xuejun Liu · San Diego, US
• Jiejun Wu · San Diego, US

Key dates

• Filing date: Sep 22, 2009
• Grant date: Dec 13, 2011
• Expiry date: Dec 30, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2502/99
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.